Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.06), $0.04 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
• Traws Pharma (TRAW) Tops Q2 EPS by 27c